Vascular News and Research

RSS

CryoLife second-quarter revenues increase 4% to record $29.3 million

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the second quarter of 2010. Revenues for the second quarter increased 4 percent to a second quarter record of $29.3 million compared to $28.2 million for the second quarter of 2009. Net income for the second quarter of 2010 was $2.9 million, or $0.10 per basic and fully diluted common share, compared to $2.5 million, or $0.09 per basic and fully diluted common share, for the second quarter of 2009.

30 Jul 2010

Supplementation of vitamin D protects vascular systems: Study

Vitamin D deficiency is associated with arterial stiffness, a risk factor for heart disease and stroke, in black teens according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). Black teens taking vitamin D supplementation of 2,000 international units (IU) per day had a decrease in central arterial stiffness.

30 Jul 2010

New study shows vitamin D deficiency is associated with arterial stiffness

Vitamin D deficiency is associated with arterial stiffness, a risk factor for heart disease and stroke, in black teens according to a new study accepted for publication in The Endocrine Society's www.endo-society.org. Black teens taking vitamin D supplementation of 2,000 international units per day had a decrease in central arterial stiffness.

29 Jul 2010

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended June 30, 2010 was $91.6 million, up 47% from $62.3 million for the same partner companies in the same period of 2009. For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45% from $121.8 million for the same partner companies for the same period of 2009.

29 Jul 2010

Covidien third-quarter 2010 net sales increase 2% to $2.56 billion

Covidien plc today reported results for the third quarter of fiscal 2010 (April - June 2010). Third-quarter net sales of $2.56 billion increased 2% from the $2.52 billion reported a year ago, with foreign exchange rate movement having no impact on the quarterly sales growth rate.

29 Jul 2010

Devax's AXXESS Biolimus A9 Eluting Coronary Bifurcation Stent System receives CE Mark approval

Devax, Inc. announced today the company received CE Mark for its AXXESS™ Biolimus A9® Eluting Coronary Bifurcation Stent System, allowing the company to initiate sales in the European Union and other countries that recognize the CE Mark.

29 Jul 2010

SIR offers five-day course that covers all aspects of acute stroke management

Catheter Lysis of Thromboembolic Stroke -an intensive five-day course offered by the Society of Interventional Radiology Oct. 24-28 in Dallas, Texas-provides interventional radiologists, neurointerventionalists, vascular neurologists and fellows-in-training with the unique educational opportunity to review, observe and discuss all aspects of acute stroke management.

29 Jul 2010

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Angiotech Pharmaceuticals, Inc. and partner Athersys, Inc. announced positive results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction, more commonly referred to as a heart attack.

29 Jul 2010

LeMaitre Vascular second-quarter sales increase 12% $14.2mm

LeMaitre Vascular, Inc., a provider of peripheral vascular devices and implants, today announced Q2 2010 financial results. The Company posted record quarterly sales of $14.2mm and record quarterly operating income of $2.0mm. The Company also increased its share repurchase program to $5mm and raised its sales and operating income guidance for 2010.

29 Jul 2010

Researchers establish new criteria for liver transplantation

Researchers at the University of California, San Francisco propose that treatments used on liver cancers beyond the established Milan criteria for liver transplantation may be appropriate for all patients with hepatocellular carcinoma who are listed for transplantation. Full details appear in the August issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

28 Jul 2010

Spectranetics second-quarter revenue increases 3% to $30.0 million

Spectranetics Corporation today reported financial results for the three and six months ended June 30, 2010.

28 Jul 2010

CPRIT awards UH $2.4 million for new multidisciplinary research

The University of Houston (UH) received a $2.4 million grant to fund the most promising young cancer researchers who are working at the cutting-edge of a new multidisciplinary approach to fighting cancer.The award is part of the latest round of grant disbursements from the Cancer Prevention and Research Institute of Texas (CPRIT), which oversees the state's new billion-dollar war on cancer. It is UH's second CPRIT grant, and the first in the science and engineering fields.

28 Jul 2010

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

NYU Langone opens vascular-targeted photodynamic therapy trial to men with localized prostate cancer

NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer. This novel, minimally invasive procedure uses a light-activated drug to deliver light energy waves by way of laser fibers in order to destroy prostate cancer cells.

28 Jul 2010

Teenage boys more likely to develop high blood pressure in early adulthood, researchers reveal

Ben-Gurion University of the Negev researchers reveal in a new, large-scale study that "normal" blood pressure at age 17 can still predict hypertension at early adulthood and that teenage boys are three to four times more likely to develop high blood pressure in early adulthood than girls.

28 Jul 2010

Calcium transfer impacts fuel mechanism for normal cell metabolism

University of Pennsylvania School of Medicine researchers have described a previously unknown biological mechanism in cells that prevents them from cannibalizing themselves for fuel. The mechanism involves the fuel used by cells under normal conditions and relies on an ongoing transfer of calcium between two cell components via an ion channel. Without this transfer, cells start consuming themselves as a way of to get enough energy.

28 Jul 2010

ProTron Technologies creates Stethotron Intra-vascular Atherosclerotic Detector

Cardiovascular and cerebrovascular disease are the major causes of death in the world. Atherosclerotic plaque, the narrowing of blood vessels, causes audible turbulence in the bloodstream. Standard and electronic stethoscopes are designed to listen to heart and lung signals between 10-300 Hz. But as these waves do not travel in straight paths, and this frequency is a physiological sound, this uncertainty of origin may cause diagnosis errors.

27 Jul 2010

Scientists discover mechanism behind flushing reaction caused by nicotinic acid treatment

Cholesterol influences the health of our hearts and blood vessels. Conventional treatment attempts to reduce the level of "bad" cholesterol, LDL cholesterol, in the blood plasma. The opposite approach, which involves increasing the concentration of "good" HDL cholesterol using nicotinic acid, has proven unpopular among patients up to now. The reason for this is that treatment with nicotinic acid has an unpleasant but harmless side-effect: the drug makes patients turn quite red in the face. Scientists at the Max Planck Institute for Heart and Lung Research in Bad Nauheim have now discovered the mechanism behind this effect, which is known as flushing. This will enable the development of flush inhibitors and thereby the more effective prevention of cardiovascular diseases.

27 Jul 2010

Report finds geographic variation in the use of carotid endarterectomy, carotid stenting

Medicare beneficiaries in some parts of the United States appear more likely to receive carotid endarterectomy, a surgical procedure to clear blockages in the artery supplying blood to the head, whereas those in other regions more often receive stents for the same condition, according to a report in the July 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

27 Jul 2010

Four research teams to study role of exercise in preventing, treating chronic diseases

Canadians will benefit from new insights into the link between physical activity and health as the Honourable Leona Aglukkaq, Minister of Health, today announced funding for four research teams through the Canadian Institutes of Health Research. These teams will study the effects of exercise on the body and its role in the prevention and treatment of chronic diseases including arthritis, breast cancer and heart disease.

27 Jul 2010

Vascular News and Research

CryoLife second-quarter revenues increase 4% to record $29.3 million

Supplementation of vitamin D protects vascular systems: Study

New study shows vitamin D deficiency is associated with arterial stiffness

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Covidien third-quarter 2010 net sales increase 2% to $2.56 billion

Devax's AXXESS Biolimus A9 Eluting Coronary Bifurcation Stent System receives CE Mark approval

SIR offers five-day course that covers all aspects of acute stroke management

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

LeMaitre Vascular second-quarter sales increase 12% $14.2mm

Researchers establish new criteria for liver transplantation

Spectranetics second-quarter revenue increases 3% to $30.0 million

CPRIT awards UH $2.4 million for new multidisciplinary research

Regeneron second-quarter total revenues increase to $115.9 million

NYU Langone opens vascular-targeted photodynamic therapy trial to men with localized prostate cancer

Teenage boys more likely to develop high blood pressure in early adulthood, researchers reveal

Calcium transfer impacts fuel mechanism for normal cell metabolism

ProTron Technologies creates Stethotron Intra-vascular Atherosclerotic Detector

Scientists discover mechanism behind flushing reaction caused by nicotinic acid treatment

Report finds geographic variation in the use of carotid endarterectomy, carotid stenting

Four research teams to study role of exercise in preventing, treating chronic diseases

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News